Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

This publication has 18 references indexed in Scilit:

• Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation
  Annals of the Rheumatic Diseases, 2002
• Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis
  Annals of the Rheumatic Diseases, 2001
• Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody
  Annals of the Rheumatic Diseases, 2000
• A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
  New England Journal of Medicine, 1999
• Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein
  New England Journal of Medicine, 1997
• Safty, efficacy, and mortality in a long‐term cohort of patients with rheumatoid arthritis taking methotrexate: Folloup after a mean of 13.3 years
  Arthritis & Rheumatism, 1997
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
  The Lancet, 1994
• The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
  Arthritis & Rheumatism, 1993
• The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
  Arthritis & Rheumatism, 1988
• LONG-TERM OUTCOME OF TREATING RHEUMATOID ARTHRITIS: RESULTS AFTER 20 YEARS
  The Lancet, 1987